Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Celyad Oncology Q4 2022 Business Update And 2023 Outlook; As Of Dec 31, 2022, The Co. Ended The Year With An Unaudited Treasury Position Of $13.3M; Co. Is Now Prioritizing Discovery Endeavors To Tackle The Major Current Limitations Of CAR T-Cell Therap…

Celyad Oncology has implemented a strategic shift from an organization focused on clinical development to one fully harnessing the true potential of its proprietary technology platforms and intellectual property The

CYAD